- Home
- CYBN vs EPIX Comparison
CYBN vs EPIX Comparison
Compare CYBN & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- EPIX
- Stock Information
- Founded
- CYBN 2019
- EPIX 2009
- Country
- CYBN Canada
- EPIX Canada
- Employees
- CYBN N/A
- EPIX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- EPIX Health Care
- Exchange
- CYBN Nasdaq
- EPIX Nasdaq
- Market Cap
- CYBN 229.8M
- EPIX 209.4M
- IPO Year
- CYBN N/A
- EPIX N/A
- Fundamental
- Price
- CYBN $11.62
- EPIX $1.72
- Analyst Decision
- CYBN Strong Buy
- EPIX Hold
- Analyst Count
- CYBN 3
- EPIX 4
- Target Price
- CYBN $45.50
- EPIX $9.50
- AVG Volume (30 Days)
- CYBN 334.2K
- EPIX 2.4M
- Earning Date
- CYBN 11-13-2024
- EPIX 12-10-2024
- Dividend Yield
- CYBN N/A
- EPIX N/A
- EPS Growth
- CYBN N/A
- EPIX N/A
- EPS
- CYBN N/A
- EPIX N/A
- Revenue
- CYBN N/A
- EPIX N/A
- Revenue This Year
- CYBN N/A
- EPIX N/A
- Revenue Next Year
- CYBN N/A
- EPIX N/A
- P/E Ratio
- CYBN N/A
- EPIX N/A
- Revenue Growth
- CYBN N/A
- EPIX N/A
- 52 Week Low
- CYBN $6.50
- EPIX $1.40
- 52 Week High
- CYBN $21.66
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- CYBN 58.44
- EPIX 23.15
- Support Level
- CYBN $10.26
- EPIX $1.75
- Resistance Level
- CYBN $12.80
- EPIX $1.89
- Average True Range (ATR)
- CYBN 1.00
- EPIX 0.19
- MACD
- CYBN 0.05
- EPIX -0.10
- Stochastic Oscillator
- CYBN 60.10
- EPIX 7.36
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.